|
KMID : 0882420190940020152
|
|
Korean Journal of Medicine
2019 Volume.94 No. 2 p.152 ~ p.158
|
|
|
Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma
|
|
Chae Hee-Jung
Yoon Dok-Hyun
|
|
|
Abstract
|
|
|
|
CD19 chimeric antigen receptor T-cell (CAR-T) therapy, a genetically engineered cell therapy, showed unprecedented efficacy in the treatment of relapsed or refractory diffuse large B-cell lymphoma. Two agents, axicabtagene ciloleucel and tisagenlecleucel, were approved by the Food and Drug Administration in 2017. However, CAR-T therapy is a treatment with complex logistics and high costs, as well as inherent adverse events, including cytokine-release syndrome and neurotoxicity. In addition, predictive biomarkers for efficacy and toxicity are lacking. Industry-academy cooperation is urgently required to develop CAR-T therapy that is effective, safe, and affordable for patients in Korea.
|
|
|
KEYWORD
|
|
|
B-cell non-Hodgkin lymphoma, Lymphoma, Large B-cell, Diffuse, Chimeric antigen receptor T-cell, CAR-T and immunotherapy
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|
|